TRANSACTION AGREEMENTTransaction Agreement • August 28th, 2018 • CytoDyn Inc. • Pharmaceutical preparations • Delaware
THIS TRANSACTION AGREEMENT (this “Agreement”), dated August 27, 2018, is entered into by and among CytoDyn Inc., a Delaware corporation (the “Company”), Point NewCo Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“NewCo”), Point Merger Corp., a Delaware corporation and wholly-owned subsidiary of NewCo (“Merger Sub”), ProstaGene, LLC, a Delaware limited liability company (“Seller”), and (solely with respect to the representations, warranties and obligations set forth in Sections 5.9(b), 7.8, 14.1(c) and 14.4(f)) Dr. Richard G. Pestell (“Dr. Pestell”). Capitalized terms used herein shall have the meaning assigned to them in Appendix A.
